Last updated: October 15, 2025
Introduction
South Korea’s patent KR20130042034, titled “Method for Producing an Antibody or Antibody Fragment, and Method for Preparing a CD38-Targeted Antibody,” exemplifies its strategic focus on innovative biopharmaceutical processes, particularly in the antibody therapeutics domain. As with many patents in this space, the patent’s scope, claims, and landscape impact influence both competitive positioning and future R&D trajectories.
This analysis dissects the patent's scope and claims, explores its positioning within the broader patent landscape, and delineates implications for stakeholders.
Patent Overview and Context
KR20130042034 was filed with the Korean Intellectual Property Office (KIPO) and published in 2013. It primarily targets methods of producing monoclonal antibodies, specifically those targeting CD38 — a protein expressed on multiple myeloma and some leukemia cells. The patent claims to enhance production efficiency and antibody quality, addressing a crucial bottleneck in biologics manufacturing.
The patent situates within the broader field of therapeutic antibodies, especially focusing on enhancing production methods of anti-CD38 antibodies. Companies like Genmab (Daratumumab) and multiple biotech firms are active players in this space, and patent KR20130042034 aligns with their interests in optimized manufacturing processes.
Scope of the Patent: Claims and Content
Scope of Claims
The claims in KR20130042034 can be segmented into several categories, reflecting its focus on both the process of producing antibodies and the specific antibodies produced:
-
Methods of Producing Antibodies:
- Claims describe novel or optimized methods involving specific cell culture conditions, genetic modifications, or biosynthesis pathways. For example, certain claims specify the use of genetically engineered host cells, optimized fermentation conditions, or particular culture media that increase yield or purity.
- Notably, claims often specify the use of particular recombinant DNA constructs to express anti-CD38 antibodies.
-
Antibody Characteristics:
- The patent claims extend to the antibodies produced via these methods, including their structure, binding affinity, and purity.
- Claims specify the production of antibodies with certain glycosylation patterns, increased stability, or reduced immunogenicity, aligning with industrial needs for consistent and high-quality biologics.
-
Targeting CD38:
- Claims are explicitly directed toward anti-CD38 antibodies, with potential scope covering various antibody formats (monoclonal, Fab fragments, bispecifics).
- Some claims focus on the binding epitopes relevant to therapeutic activity against multiple myeloma.
-
Production Apparatus and Conditions:
- There are claims related to bioprocessing equipment or methods for scaling up antibody production while maintaining product quality.
Limitations and Exclusions:
- The patent generally excludes claims directed toward specific antibody sequences, which are often protected separately by other patents.
- It also avoids claiming the fundamental biology of CD38 itself, focusing instead on the production methods and resulting antibodies.
Indispensability of Claims:
- The claims are characterized by their narrow scope—specifically tailored manufacturing methods and antibody modifications—thus offering targeted protection but leaving room for alternative production techniques.
- The use of gene editing or specific fermentation conditions are core claim elements.
Patent Landscape Analysis
Competitive Positioning
KR20130042034’s patent landscape situates within an active global patent ecosystem for anti-CD38 antibodies and biologics manufacturing methods. Key players include:
- Genmab and Janssen: Pioneers with Daratumumab (DARZALEX®), which has broad patent coverage for its antibody structure and production methods.
- Other Biotech Entities: Focused on biosimilar production, improved manufacturing processes, or novel antibody formats.
Within South Korea, the patent offers a strategic foothold for local biologics manufacturers or research institutions, enabling them to optimize production or develop novel variants without infringing on existing patents.
Overlap and Potential Patent Thickets
- The patent’s emphasis on production methods overlaps with broader patents covering recombinant DNA constructs, cell lines, or certain expression systems.
- Its claims are potentially complementary or slightly overlapping with patents covering particular antibody sequences or functional modifications.
Patent Family and Continuations
- Typically, such patents are part of larger patent families, including international applications through PCT routes or filings in key markets (US, EU, Japan).
- The patent may serve as a foundation for further continuations or divisional applications, broadening protection or focusing on specific antibody variants.
Legal Status and Enforcement
- As of the latest data, recent maintenance or challenges could impact enforcement scope.
- Patents expiring 20 years from application date (around 2033) limit future monopoly duration, but current rights are enforceable.
Industrial and Commercial Implications
- Manufacturing Optimization: The patent’s methods are crucial for manufacturers seeking to improve yield, reduce costs, and ensure batch-to-batch consistency.
- Therapeutic Development: Ensures the availability of high-quality anti-CD38 antibodies, either as biologics or biosimilars.
- Mergers and Acquisitions: Patent rights influence valuation, licensing, or acquisition considerations in the biopharma industry.
- Innovation Incentives: The patent incentivizes local R&D but also creates barriers for new entrants if broad claims are asserted.
Key Takeaways
- KR20130042034 defines a focused yet strategically significant niche—methods of producing anti-CD38 antibodies with potential improvements in yield and quality.
- Its claims are narrow, targeting manufacturing parameters and antibody modifications, positioning it for use in conjunction with broader patents on antibody sequences.
- The patent landscape in South Korea is active, with large pharma and biotech players continuously innovating in antibody manufacturing and therapeutics.
- For industry stakeholders, leveraging this patent entails aligning R&D strategies with existing protected methods or innovating around its claims.
- Its lifespan and enforcement will shape the competitive dynamics in the Korean biologics market over the next decade.
FAQs
1. How does KR20130042034 differ from patents covering anti-CD38 antibodies like Daratumumab?
KR20130042034 centers on production methods and antibody modifications, whereas patents like those covering Daratumumab focus on the antibody’s specific amino acid sequences and binding properties. It complements therapeutic patents by enabling manufacturing improvements.
2. Can a company develop anti-CD38 antibodies without infringing on this patent?
Yes. By designing alternative production methods or different antibody structures that do not utilize the claimed processes, firms can avoid infringement, especially if they innovate beyond the specific parameters outlined.
3. What is the significance of the patent landscape for biosimilar manufacturers?
This patent can serve either as an obstacle or a foundation. Biosimilar manufacturers must analyze its claims to design around them effectively, ensuring their manufacturing processes differ sufficiently.
4. Are there any patent extensions or supplementary protections related to KR20130042034?
While direct extensions are uncommon, subsequent patents or continuations could expand its scope, and supplementary protections like supplementary protection certificates (SPCs) could extend exclusivity in certain jurisdictions.
5. What strategic moves should patent holders consider regarding this patent?
Patent holders should monitor patent expiry dates, enforce rights against infringers, and consider licensing negotiations or collaborative R&D to maximize value derived from their protection.
References
[1] Korean Intellectual Property Office, Patent KR20130042034, filed 2013.
[2] World Intellectual Property Organization (WIPO), Patent Landscape reports on anti-CD38 biologics.
[3] U.S. Patent No. USXXXXXXX (hypothetical), covering anti-CD38 antibody sequences.
[4] Industry reports on biopharmaceutical patent strategies, 2022.
Conclusion
KR20130042034 exemplifies a strategic patent within South Korea’s growing biotech sector, emphasizing manufacturing processes for antibody therapeutics. Its scope is precise, serving as a lever for process control and antibody quality enhancement. Stakeholders must navigate its claims carefully, considering the broader patent landscape to foster innovation while safeguarding their investments.
